C

Corbus Pharmaceuticals Holdings
D

CRBP

16.750
USD
0.63
(3.91%)
مغلق
حجم التداول
0
الربح لكل سهم
-4
العائد الربحي
-
P/E
-3
حجم السوق
201,735,995
أصول ذات صلة
    A
    ACAD
    -0.240
    (-1.41%)
    16.790 USD
    A
    AKTX
    -0.32000
    (-13.56%)
    2.04000 USD
    C
    CARA
    -0.01170
    (-3.57%)
    0.31600 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    M
    MRNS
    -0.00350
    (-1.13%)
    0.30490 USD
    T
    TLRY
    -0.04500
    (-3.25%)
    1.34000 USD
    Z
    ZYNE
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار

العنوان: Corbus Pharmaceuticals Holdings

القطاع: Healthcare
الصناعة: Biotechnology
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.